AffaMed Digital, a company wholly owned by AffaMed Technologies—a joint venture between AffaMed Therapeutics and SIFI S.p.A.—has announced the first patient enrollment in a clinical study for its AMD201 at the Beijing Tiantan Hospital. This marks a significant step in the development of digital therapies for post-stroke cognitive impairment (PSCI).
Understanding Post-Stroke Cognitive Impairment (PSCI)
PSCI is a clinical syndrome characterized by cognitive impairment that occurs 3-6 months after a stroke event. These impairments can persist for many years, Seriously affecting the daily life of patients, reducing long-term survival rates, increasing disability and hospitalization rates. AMD201 is a computer-based cognitive training software that includes a series of training games adapted from classic research paradigms, offering a new non-pharmacological treatment to improve specific cognitive impairments in PSCI patients.
Partnership and Licensing Deal for Digital Therapy Development
In late 2021, AffaMed Therapeutics partnered with Beijing Tiantan Hospital and Infinite Brain Technologies Limited to delve into the application and development of digital therapy in nervous system diseases. The company further expanded its reach by inking a licensing deal with IBT, securing global rights to the latter’s digital therapy in PSCI and other indications. The first investigator-initiated trial in PSCI, led by Professor Wang Yongjun, director of Tiantan Hospital, was concluded at the beginning of last year, laying the groundwork for further research and development in this field.-Fineline Info & Tech
